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OBJECTIVES Our objective was to determine whether a strategy of intended incomplete percutaneous
transluminal coronary angioplasty revascularization (IR) compromises long-term patient outcome.
BACKGROUND Complete angioplasty revascularization (CR) is often not planned nor attempted in patients
with multivessel coronary disease, and the extent to which this influences outcome is unclear.
METHODS Before randomization, in the Bypass Angioplasty Revascularization Investigation, all angio-
grams were assessed for intended CR or IR via angioplasty. Outcomes were compared among
patients with IR intended if assigned to angioplasty, randomized to coronary artery bypass
graft surgery (CABG) versus angioplasty; and within angioplasty patients only, among
patients with IR versus CR intended.
RESULTS At 5 years, there was a trend for higher overall (88.6% vs. 84.0%) and cardiac survival (94.5% vs.
92.1%) in CABG versus angioplasty patients with IR intended. The excess mortality in
angioplasty patients occurred solely in diabetic subjects; overall and cardiac survival were similar
among nondiabetic CABG and angioplasty patients. Freedom from myocardial infarction (MI) at
5 years was higher in nondiabetic CABG versus angioplasty patients (92.4% vs. 85.2%, p 5 0.02),
yet was similar to the rate observed (85%) in nondiabetic CABG and angioplasty patients with CR
intended. Five-year rates of death, cardiac death, repeat revascularization and angina were similar
in all angioplasty patients with IR versus CR intended. However, a trend for greater freedom from
subsequent CABG was seen in CR patients (70.3% vs. 64.0%, p 5 0.08).
CONCLUSIONS Intended incomplete angioplasty revascularization in nondiabetic patients with multivessel
disease who are candidates for both angioplasty and CABG does not compromise long-term
survival; however, subsequent need for CABG may be increased with this strategy. Whether
the risk of long-term MI is also increased remains uncertain. (J Am Coll Cardiol 1999;33:
1627–36) © 1999 by the American College of Cardiology
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Most patients undergoing coronary artery bypass graft
surgery (CABG) receive complete or nearly complete revas-
cularization, and this result appears to positively influence
long-term prognosis (1–7). In contrast, complete revascu-
larization may be planned and attempted in 50% or less of
patients treated with percutaneous transluminal coronary
angioplasty, and the extent to which lack of complete initial
revascularization influences outcome is less clear (8–17).
Late survival and survival free of myocardial infarction (MI)
appear similar in patients with and without complete
revascularization after angioplasty (8–10). However, the
need for subsequent CABG is usually much higher in
patients with incomplete compared with those with com-
plete revascularization after angioplasty (11–18). This
higher rate of CABG after incomplete angioplasty revascu-
larization may be the result of lack of both initial procedural
success and of long-term symptom relief.
The Bypass Angioplasty Revascularization Investigation
(BARI) tested the hypothesis that an initial use of angio-
plasty compared with CABG in patients with multivessel
disease and severe angina or ischemia requiring revascular-
ization which could be approached by either procedure did
not compromise survival during a five-year period (19,20).
Angiographic eligibility required consent of both the angio-
plasty operator and the surgeon, but expectation of complete
revascularization by either procedure was not a requirement
for inclusion in BARI. Overall, five-year survival did not
differ significantly between the two treatments despite the
fact that 91% of significant lesions were bypassed in the
CABG patients compared with only 54% of clinically
important lesions successfully dilated in the angioplasty
patients (20).
As part of the screening process in BARI, an angio-
graphic assessment was made to determine the suitability
and operator willingness to attempt each $50% lesion with
angioplasty revascularization. The same determination was
also made to determine lesion suitability for CABG, al-
though this is not the subject of the present report. Thus,
before patient randomization, a determination of intended
complete (CR) or intended incomplete (IR) angioplasty
revascularization was made such that the two revasculariza-
tion assignments (CABG and angioplasty) can be compared
without bias within the IR intended and within the CR
intended groups. In addition, the effect of IR intended on
end points such as angina and need for repeat revascular-
ization can be studied within angioplasty patients only, but
not without bias, because the grouping of these patients
reflects the selection made by the investigator. The purpose
of this report was to assess whether angioplasty compro-
mises outcome in patients where it cannot be expected to
achieve complete revascularization, and whether such pa-
tients should always undergo CABG as their initial proce-
dure.
METHODS
Patient selection. Patients were eligible for BARI if they
had clinically severe angina or objective evidence of ischemia
requiring revascularization, multivessel coronary disease
suitable for both angioplasty and CABG and informed
consent for random assignment (19,20). Between August
1988 and August 1991, 1,829 patients were enrolled at 18
centers, 16 in the United States and two in Canada, of
whom 914 were randomly assigned to undergo and 892
received CABG, and 915 were randomized to undergo
angioplasty and 904 received this treatment. No significant
difference was observed between the two groups in the
primary end point of mortality at five years, 89.3% for
patients assigned to CABG versus 86.3% for those assigned
to angioplasty, p 5 0.19 (20).
Figure 1 shows the a priori (e.g., before randomization)
determination of intended completeness of revascularization
(if assigned to angioplasty) in the BARI population. Incom-
plete revascularization was planned in 624 patients (34.1%),
CR in 1,196 (65.4%) and intended completeness of revas-
cularization was not determined in 9 (0.5%). After random
assignment, 612 patients with planned CR versus 301 with
Abbreviations and Acronyms
BARI 5 Bypass Angioplasty Revascularization
Investigation
CABG 5 coronary artery bypass graft surgery
CR 5 complete revascularization
IR 5 incomplete revascularization
MI 5 myocardial infarction
Figure 1. Diagram of the Bypass Angioplasty Revascularization
Investigation population showing the number of patients with
complete revascularization (CR) versus incomplete revasculariza-
tion (IR) intended (if assigned to percutaneous transluminal
coronary angioplasty [PTCA]) and for each group, random assign-
ment and actual treatment by coronary artery bypass graft surgery
(CABG) or PTCA. *Refers to eligible patients who agreed to be
randomized although the intended completeness of revasculariza-
tion was assessed for all patients before study entry. **In 311 of the
624 patients clinically important lesions not intended for revascu-
larization were involved.
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planned IR were assigned to and 600 versus 291 received
CABG, whereas 584 versus 323 were assigned to and 579
versus 317 received angioplasty. Among IR patients,
roughly one half had one or more lesions considered by the
angioplasty operator to be clinically important but not
intended for angioplasty; in the other half, one or more
borderline lesions were not intended for angioplasty.
Bypass Angioplasty Revascularization Investigation an-
giographic definitions. Angiographically significant le-
sions were defined as $50% stenosis in a vessel $1.5 mm as
measured by electronic calipers (21). The number of dis-
eased vessels was defined as the number of the three major
coronary perfusion territories (anterior, lateral and infero-
posterior) supplied by a vessel with an angiographically
significant lesion. To estimate the amount of myocardium at
risk, a global percent jeopardy index was calculated as the
ratio of left ventricular territory subtended by terminal
coronary segments compromised by significant lesions to
the sum of all left ventricular territory supplied by major
terminal coronary branches (21). Lesion complexity was
categorized as type A, B and C using American Heart
Association/American College of Cardiology consensus
panel criteria (22). Flow distal to each stenosis was catego-
rized by Thrombolysis in Myocardial Infarction flow criteria
(23). A lesion was considered successfully dilated if there
was a .20% reduction in stenosis with a residual stenosis
,50% and TIMI flow grade 3.
Data collection. Consecutive patients were screened for
clinical eligibility and presence of multivessel disease at the
time of angiography, and the angiograms were reviewed to
determine suitability for both angioplasty and bypass sur-
gery. Although the protocol called for anticipation of
successful relief of the major areas of ischemia, the potential
for complete revascularization was not a requirement. The
BARI investigators recognized the limitations of trying to
describe prospectively all the features that define technical
suitability for angioplasty and CABG. Therefore, the final
determination of eligibility involved the subjective judgment
of different angioplasty operators and cardiac surgeons who
were all highly experienced and BARI certified (19,24).
Specific reasons for anticipated lack of efficacy or safety were
recorded.
Before randomization, clinical site investigators specified
the extent and severity of coronary disease and which
coronary lesions would be selected for revascularization (if
assigned to angioplasty). Lesion complexity and clinical
relevance were also recorded. The angiograms of enrolled
patients were also interpreted by a Central Radiographic
Laboratory except for the clinical relevance and appropri-
ateness of lesions for revascularization. Consequently, the
results of the Central Radiographic Laboratory interpreta-
tion were not used in this report.
Details of the angioplasty and bypass surgery procedures
and follow-up clinical events including procedural and
long-term mortality rates, recurrence of angina and repeat
revascularization were recorded on standardized forms. Rest
electrocardiograms were routinely collected at study entry,
before and after all coronary revascularization procedures, at
scheduled follow-up and for all suspected myocardial infarct
events. A central electrocardiographic laboratory coded all
Q-wave events blinded by initial treatment assignment (25).
According to protocol, cardiac enzymes were not used to
define myocardial infarction within 96 h of a revasculariza-
tion procedure (19,25). Cause of death was classified by an
independent Mortality and Morbidity Classification Com-
mittee. Cardiac death was defined as: death less than 1 h
after onset of cardiac symptoms, or within 1 h to 30 days
after a documented or probable myocardial infarction, or
death from intractable congestive heart failure, cardiogenic
shock or other documented cardiac causes.
Assessment of lesion clinical relevance and intention for
angioplasty. According to the clinical judgment of the
angioplasty operator and surgeon, each significant lesion
was rated before randomization as clinically important,
borderline or not relevant (small territory or nonviable
myocardium). A lesion was rated as clinically important if it
was felt to be responsible for or to contribute significantly to
the patient’s ischemic syndrome and if the myocardial
territory distal to the lesion was viable and large enough to
warrant revascularization. A borderline lesion was a lesion
for which revascularization was not required or necessary
but was often performed incidentally during treatment of
significant lesions (26). Diffuse lesions, which constituted
4% of all significant lesions, were generally not rated a priori
for clinical relevance, and were considered to be clinically
important in this report. Only approximately 2% of all
significant lesions were total occlusions supplying a small
territory/nonviable myocardium, and they were excluded
from the analysis. Intended completeness of revasculariza-
tion was determined on the basis of all lesions considered
clinically important or borderline and whether or not these
lesions were declared as both suitable and intended to be
dilated with angioplasty (26).
This determination yielded 624 patients with $1 clini-
cally important or borderline lesions considered not in-
tended for angioplasty and hence representing a strategy of
IR intended (Fig. 1). For subanalyses, patients were further
categorized in a nonrandomized fashion, according to
whether clinically important lesions were intended or not
intended for angioplasty.
Statistical analysis. Groups of patients were compared in
two ways. First, among patients with IR intended if as-
signed to angioplasty, those randomized to CABG versus
angioplasty were compared. Second, among angioplasty
patients only, those with a strategy of CR intended versus
IR intended were compared (nonrandomized comparison).
The second nonrandomized comparison was performed
because some end points (e.g., angina, repeat revasculariza-
tion) may be most informative when compared among
angioplasty patients only. Differences in proportions of
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baseline clinical and angiographic characteristics, and the
prevalence of angina during follow-up were assessed by use
of chi-square tests. Similarly, differences in continuous
measures of these factors were assessed by Student t tests.
The Kaplan–Meier estimate (27) was used to calculate
five-year freedom from untoward event rates which included
total mortality, cardiac mortality, MI, repeat CABG, repeat
angioplasty, and any repeat revascularization. These esti-
mates were restricted to patients who received their assigned
treatment, and were compared by the use of log-rank
statistic.
Power calculations were made assuming a one-sided
hypothesis with a type I error of 0.05. We postulated that:
a) CABG patients have a greater freedom from events than
angioplasty patients with IR intended and b) angioplasty
patients with CR intended have a greater freedom from
events than angioplasty patients with IR intended. Risk
ratios and percent power were calculated given the fixed
sample size and actual differences in event rates. Next, we
calculated the between-group differences and risk ratios that
would be necessary to achieve 80% power given our sample
size and the event rates observed in the two lower risk
reference groups.
RESULTS
Baseline clinical and angiographic characteristics. Table
1 presents the baseline clinical and angiographic character-
istics of the study patients. Overall, patients with IR
intended if assigned to angioplasty had a worse baseline
profile than patients with CR intended. Clinically, they had
a significantly higher prevalence of prior MI, congestive
heart failure, treated diabetes and peripheral vascular dis-
ease. However, among patients with IR intended, those
randomized to CABG versus angioplasty were similar on all
clinical characteristics.
Compared with patients with CR intended if assigned to
angioplasty, patients with IR intended had more triple
vessel disease, clinically important lesions, total occlusions
and class C lesions. They also had a lower ejection fraction,
a higher wall motion score and a higher percentage of
jeopardized myocardium. Among the 624 patients with IR
intended, baseline angiographic characteristics were similar
between patients randomized to CABG versus those ran-
domized to angioplasty. However, despite the protection of
randomization and similarity of clinical and angiographic
characteristics, CABG patients had a higher proportion of
clinically important lesions not intended compared with
angioplasty patients.
Initial procedural outcome in patients who received their
assigned treatment. Table 2 presents the initial procedural
outcome of the 608 patients with IR intended if assigned to
angioplasty who received their assigned treatment, and the
579 angioplasty patients with CR intended. Coronary artery
bypass graft surgery patients seemed to be nearly completely
revascularized with an average of 2.9 grafts and 3.3 distal
anastomoses per patient, although 13.2% had at least one
diseased vessel after the procedure. By comparison, a sub-
stantial proportion of angioplasty patients with both CR
and IR intended were incompletely revascularized at the
initial angioplasty. This occurred because only about half of
all lesions initially intended for angioplasty were both
attempted and successfully dilated. However, there was a
clear and significant separation in the extent of revascular-
ization achieved (as determined from the mean percent of
myocardium jeopardized after angioplasty) between angio-
plasty patients with CR and those with IR intended.
Despite the differences in the initial extent of revascular-
ization achieved, the incidence of in-hospital death and
death/Q-wave MI did not differ significantly between an-
gioplasty patients with IR intended and both CABG
patients with IR intended and angioplasty patients with CR
intended. Similarly, among angioplasty patients only, the
incidence of abrupt closure, emergent and nonemergent
CABG and repeat angioplasty was similar between the CR
and IR groups.
Freedom from untoward events—randomized compari-
son of CABG and angioplasty patients with IR intended
if assigned to angioplasty. Table 3 presents freedom from
untoward event rates at five years for the randomized
treatment comparison of patients with IR intended if
assigned to angioplasty (CABG vs. angioplasty). There was
a nonsignificant trend for CABG patients to have higher
five-year survival and cardiac survival than angioplasty
patients. However, almost all of the excess mortality oc-
curred in the 142 patients with treated diabetes, with
identical five-year cardiac survival (95.7%) seen between 466
nondiabetic CABG and angioplasty patients. Five-year
freedom from MI was higher in all as well as nondiabetic
CABG versus angioplasty patients. When the analysis was
restricted to patients with class C or borderline lesions, the
five-year results were similar to those of the entire cohort of
patients with IR intended. Not surprisingly, the need for
repeat revascularization was substantially greater in angio-
plasty versus CABG patients. In addition, CABG patients
were more likely to be free of angina at five years.
As shown in Table 4, our study was underpowered to
detect statistically significant mortality and especially car-
diac mortality differences among CABG versus angioplasty
patients with IR intended. On the other hand, the actual
versus required risk ratios for MI and death/MI suggest that
the study had adequate power to detect a clinically mean-
ingful difference for these end points.
Freedom from untoward events at five years—
nonrandomized comparison among angioplasty patients
(CR vs. IR intended). Table 5 presents freedom from
untoward event rates at 5 years for the nonrandomized
comparison of angioplasty patients only (CR vs. IR intend-
ed). Despite an overall worse baseline clinical and angio-
graphic profile in the IR group, freedom from death,
cardiac death, MI and repeat revascularization (CABG/
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angioplasty) did not differ significantly between all as well as
nondiabetic angioplasty patients in whom incomplete versus
complete revascularization was intended. In addition, the
prevalence of angina at five years did not differ between
angioplasty patients with planned IR versus CR. Similarly,
the prevalence and severity of angina were similar between
angioplasty patients with planned IR versus CR throughout
five-year follow-up (Fig. 2). Finally, there was a nonsignif-
icant trend for more CABG during follow-up in angioplasty
patients with planned IR versus those with planned CR.
Given the sample size of 579 patients in the reference
group (angioplasty patients with CR intended), the study
has sufficient power to detect moderate differences in clinical
outcome among angioplasty patients with CR versus IR
intended. In particular, the sample size was sufficiently large
to detect a moderate excess of CABG at five years in the
group with IR intended (Table 6).
DISCUSSION
In patients with multivessel coronary artery disease who are
referred for revascularization and who are suitable for both
angioplasty and CABG, the choice of procedure often
presents a clinical dilemma. Recent randomized clinical
trials have consistently shown that, overall, midterm survival
(between one and five years) and survival without myocar-
dial infarction do not differ significantly between the two
treatment strategies, but that an initial angioplasty strategy
is usually associated with a greater incidence of repeat
revascularization and more residual angina during follow-
Table 1. Baseline Clinical and Angiographic Characteristics (n 5 1820)
Baseline Characteristics
All Randomized Patients
Patients With IR Intended if
Assigned to PTCA
CR Intended if
Assigned to PTCA
(n 5 1,196)
IR Intended if
Assigned to PTCA
(n 5 624)
Randomized
to CABG
(n 5 301)
Randomized
to PTCA
(n 5 323)
Age (mean yr) 61.3 61.9 61.4 62.3
Age $65 yr (%) 38.1 40.1 38.9 41.2
Female (%) 28.2 23.9 22.6 25.1
Black (%) 5.5 7.4 8.6 6.2
Hx MI (%) 51.2* 59.5 62.1 57.0
Hx CHF (%) 7.5† 11.1 9.3 12.7
Hx hypertension (%) 48.4 50.3 51.8 48.9
Hx treated diabetes (%) 17.1* 23.7 23.6 23.8
Hx hypercholesterolemia (%) 39.3 40.4 40.9 39.9
Family Hx of CAD (%) 49.9 47.8 45.2 50.2
Smoking (%)
Current 25.8 24.5 22.6 26.3
Ever 70.6 70.5 68.4 72.5
Angina status (%)
Stable—class I/II 13.6 13.0 13.6 12.4
Stable—class III/IV 16.7 15.9 15.6 16.1
Unstable 62.3 63.9 63.1 64.7
Only with acute MI 5.7 5.1 5.3 5.0
None 1.7 2.1 2.3 1.9
Peripheral vascular disease (%) 7.2‡ 11.2 11.0 11.5
Regular exercise program (%) 14.1‡ 19.2 17.6 20.7
Triple vessel disease (%) 36.3* 51.0 48.2 53.6
Significant lesions (mean) 3.2* 3.8 3.8 3.9
Clinically important lesions (mean) 2.9* 3.6 3.6 3.6
$1 clinically important lesions not
intended for PTCA
0.0* 49.8 55.8§ 44.3
$1 total occlusions (%) 25.1* 58.3 62.1 54.8
$1 class C lesions (%) 28.3* 62.0 65.8 58.5
Proximal LAD disease (%) 36.6 35.6 32.6 26.0
Ejection fraction (mean) 58.3* 55.6 55.7 55.4
Ejection fraction ,50 (%) 18.8* 29.0 26.9 30.9
Myocardium jeopardized (mean %) 60.2* 63.4 63.0 63.7
Wall motion score (mean) 7.1* 8.0 8.0 7.9
*p , 0.001, †p , 0.05, ‡p , 0.01 for comparison of patients with CR/IR intended. §p , 0.01, all other comparisons of CABG vs. PTCA patients, p . 0.05.
CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease; CHF 5 chronic heart failure; CR 5 complete revascularization; Hx 5 history; IR 5
incomplete revascularization; LAD 5 left anterior descending artery; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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up. Some trials have included only patients who could be
completely revascularized by angioplasty (28,29), whereas
others enrolled patients in whom incomplete revasculariza-
tion was expected (30–32). In BARI, incomplete revascu-
larization was permitted although the protocol required
relief of the major ischemic areas. The BARI design was
unique in that the operators had to declare a priori (e.g.,
before randomization) their intention to treat or not to treat
by angioplasty each significant lesion in a given patient and
also to rate each lesion (whether intended or not) according
to its clinical importance. Thus, the BARI design allowed
for an unbiased prospective evaluation of the outcome of
angioplasty patients with intended incomplete revascular-
ization versus randomly matched CABG patients, and a
nonrandomized comparison of outcomes between angio-
plasty patients with intended incomplete versus complete
revascularization.
The group with intended incomplete angioplasty revas-
cularization amounted to one third of all BARI patients.
Clearly, this group had more clinical risk factors, more
severe coronary artery disease, (particularly triple vessel
disease with chronic total occlusions or other class C
lesions) and more significant left ventricular dysfunction
than the group in whom complete revascularization was
intended. In addition, nearly half of these patients had
lesions considered clinically important which were not
intended for angioplasty. We postulated that in patients
with multivessel disease in whom incomplete angioplasty
revascularization was intended, an initial strategy of CABG
might result in a better five-year survival than an initial
strategy of angioplasty. Even among patients with intended
complete angioplasty revascularization, not all intended
lesions are actually attempted, and not all attempted lesions
are successfully dilated. Therefore, what is achieved at
angioplasty is usually less than what was intended initially,
and this is true equally for patients with intended complete
or incomplete revascularization. The aim of this study was
to examine the influence of an intended incomplete angio-
plasty revascularization strategy on long-term outcome, not
taking into account the degree of revascularization actually
achieved as reported in several recent studies (6–18).
Freedom from untoward events (death, MI, angina) in
relation to intended completeness of revascularization (if
randomized to angioplasty). After accounting for the
excess mortality previously noted in randomized angioplasty
patients with diabetes, five-year total mortality and cardiac-
only mortality did not differ significantly between angio-
Table 2. Initial Procedural Outcome (Among 608 CABG and PTCA Patients With IR
Intended and 579 PTCA Patients With CR Intended if Randomized to PTCA Who Received
Their Assigned Treatment)
CABG Patients
With IR Intended if
Assigned to PTCA
(n 5 291)
PTCA Patients
IR Intended
(n 5 317)
CR Intended
(n 5 579)
Extent of initial revascularization
No. of grafts (mean) 2.9
No. of IMA grafts (mean) 0.9
IMA graft received (%) 82.8
No. of distal sites (mean) 3.3
Diseased vessel(s) post-CABG (%)* 13.2
Lesions attempted (mean)† 2.1 2.5
$1 lesion successful (%)‡§ 85.7 90.9
All attempted lesions successful (%)‡ 57.6 57.8
All intended lesions successful (%) 51.1 45.4
Myocardium jeopardized (%) 18.4 32.3
Post-PTCA (mean)†\
Complications of the initial procedure
In-hospital death (%) 1.0 0.3 1.6
In-hospital Q wave MI (%) 2.4 2.5 1.9
In-hospital death/Q wave MI (%) 3.4 2.8 3.1
Abrupt closure (%) 9.5 9.5
Emergency CABG (%) 6.3 6.4
Nonemergency CABG (%) 3.8 4.0
Emergency PTCA (%) 2.2 2.1
Nonemergency PTCA (%) 1.9 1.0
CHF or pulmonary edema (%) 2.4 2.5 2.3
*Based on either an intended vessel not grafted. †p , 0.001. ‡Refers only to patients with one or more attempted lesions. §p ,
0.05. \Includes all significant lesions ($50% stenosis) irrespective of a priori judgment of clinical importance.
IMA 5 internal mammary artery. Other abbreviations as in Table 1.
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plasty, and CABG patients with intended incomplete an-
gioplasty revascularization. This comparison held true for
the subset of 311 patients with clinically important lesions
not intended for dilation. These findings suggest that in
nondiabetic patients with clinical and angiographic charac-
teristics similar to those seen in BARI patients, an initial
strategy of intended incomplete angioplasty revasculariza-
tion probably does not increase the risk of five-year mortal-
ity compared with an initial strategy of CABG. These
results are in agreement with previous reports which suggest
that midterm survival is similar with and without complete
revascularization after angioplasty (8–10).
Five-year freedom from MI was significantly less in
nondiabetic angioplasty patients with intended incomplete
revascularization than in similar randomly assigned CABG
patients (85.2% vs. 92.4%). Although our study had ade-
quate power to detect a clinically meaningful difference
between treatment groups for freedom from MI and free-
dom from death/MI, the interpretation of these findings
remains unclear given that the five-year freedom from MI
was 85.1% and 84.7% in the groups of nondiabetic patients
with complete revascularization intended (angioplasty and
CABG, respectively). Because CABG and angioplasty pa-
tients with complete revascularization intended had, on
average, a more favorable baseline profile than patients with
intended incomplete revascularization, it would seem that
the rate of freedom from MI of 92.4% at 5 years in
nondiabetic CABG patients with intended incomplete re-
vascularization if assigned to angioplasty is unexpectedly
high. In the BARI trial, non–Q-wave MI was not diag-
nosed within 96 h of either angioplasty or CABG because of
Table 3. Freedom From Untoward Events at Five Years
(CABG vs. PTCA Patients With IR Intended if Assigned to
PTCA)
Event
CABG
(n 5 291)*
(%)
PTCA
(n 5 317)†
(%)
p Value
CABG
Versus
PTCA
Death
All patients 88.6 84.0 0.08
Nondiabetic patients 92.1 90.1 0.37
Cardiac death
All patients 94.5 92.1 0.21
Nondiabetic patients 95.7 95.7 0.95
MI
All patients 89.8 84.1 0.05
Nondiabetic patients 92.4 85.2 0.02
Death/MI
All patients 79.9 72.5 0.02
Nondiabetic patients 84.5 78.1 0.05
CABG
All patients 99.4 64.0 ,0.0001
Nondiabetic patients 99.3 63.9 ,0.0001
CABG/PTCA
All patients 91.1 42.8 ,0.0001
Nondiabetic patients 91.8 43.7 ,0.0001
Angina
All patients 87.1 75.6 0.006
Nondiabetic patients 88.7 74.4 0.003
*n 5 223 nondiabetic patients. †n 5 243 nondiabetic patients. Abbreviations as in
Table 1.
Table 4. Power Calculations (All CABG vs. PTCA Patients With IR Intended if Assigned
to PTCA)
Event
Actual Event Rates and Power Required for 80% Power
Rate Difference
CABG 2 PTCA (%)
Risk
Ratio
%
Power
Rate Difference
CABG 2 PTCA (%)
Risk
Ratio
Death 4.6 1.40 50 7.2 1.63
Cardiac death 2.4 1.44 32 5.6 2.02
MI 5.7 1.56 67 6.9 1.68
Death/MI 7.4 1.37 69 8.7 1.43
Abbreviations as in Table 1.
Table 5. Freedom From Untoward Events at Five Years (PTCA
Patients With CR vs. IR Intended)
Event
CR
Intended
(n 5 579)*
(%)
IR
Intended
(n 5 317)†
(%)
p Value
CR Versus
IR Intended
Death
All patients 87.5 84.0 0.13
Nondiabetic patients 91.6 90.1 0.57
Cardiac death
All patients 92.0 92.1 0.92
Nondiabetic patients 95.3 95.7 0.76
MI
All patients 83.8 84.1 0.91
Nondiabetic patients 85.1 85.2 0.89
CABG
All patients 70.3 64.0 0.08
Nondiabetic patients 71.8 63.9 0.05
CABG/PTCA
All patients 46.3 42.8 0.48
Nondiabetic patients 48.2 43.7 0.34
Angina
All patients 79.8 75.6 0.22
Nondiabetic patients 79.8 74.3 0.23
*n 5 484 nondiabetic patients. †n 5 243 nondiabetic patients. Abbreviations as in
Table 1.
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the difficulty of interpreting the clinical significance of
cardiac enzyme elevations after bypass surgery. Whether
this might have influenced long-term infarction rates is
unknown, but appears unlikely. Moreover, the finding of
identical rates of late cardiac deaths but higher rates of
nonfatal MI after angioplasty than CABG in nondiabetic
patients, if confirmed, would be hard to explain. The
finding that freedom from MI at five years is greater in
CABG patients with intended incomplete than in those
with intended complete revascularization if assigned to
angioplasty was also unexpected. A possible explanation,
however, could be that surgical bypass of lesions considered
to be of borderline clinical importance often leads to
occlusion of both the graft and the native vessel with a
poorer outcome than if the vessels had not been attempted.
Finally, previous studies have shown that midterm Q wave
MI rates are similar in patients with multivessel disease in
whom complete or incomplete revascularization is achieved
after angioplasty (8–10,18). Thus, whether intended in-
complete angioplasty revascularization adversely influences
the long-term risk of MI remains unclear at this time.
The prevalence of angina during follow-up was signifi-
cantly higher in angioplasty patients with intended incom-
plete revascularization compared with randomly assigned
CABG patients. However, the excess angina prevalent in
angioplasty patients appeared unrelated to whether or not
complete revascularization was intended. Thus, the specific
angiographic characteristics and clinical judgment which
determine whether an operator intends to attempt complete
revascularization do not seem to influence the occurrence of
angina after angioplasty revascularization.
Freedom from repeat revascularization. Despite similar-
ity in the need for repeat revascularization (CABG or
angioplasty), a trend for more follow-up CABG was seen in
angioplasty patients with incomplete compared with angio-
plasty patients with complete revascularization intended.
Our sample size was sufficiently large to detect a moderate
excess of CABG at five years in the group with IR intended.
Given these results and the results of previous studies
(11–18), a strategy of intended incomplete angioplasty
revascularization seems to increase the likelihood of a
patient requiring subsequent CABG (e.g., to alleviate symp-
toms of ischemia). However, the apparent excess CABG
seen in angioplasty patients with intended incomplete re-
vascularization did not adjust for adverse clinical and angio-
graphic characteristics which were more common in these
patients. The relatively modest difference in CABG in our
study in comparison with previous reports (14,15) may
reflect the a priori declaration of intended completeness of
revascularization, as opposed to studies of achieved com-
pleteness of revascularization where, by definition, all pa-
tients with failed angioplasty, are considered incompletely
revascularized and probably more likely to undergo CABG.
Study limitations. Patients were enrolled in BARI be-
tween August 1988 and August 1991. Because of the
uncertainty then about the outcome of procedures involving
new technologies such as stents, atherectomy and laser
angioplasty, these new devices were prohibited as part of the
initial angioplasty strategy. Thus, our data are particularly
relevant to the large number of patients with multivessel
coronary disease still managed exclusively with balloon
angioplasty. Ongoing studies will hopefully determine how
the addition of stents and other devices to conventional
angioplasty influence the results of interventional cardiology
as compared with current surgical techniques. In this study,
we assessed intended incomplete anatomic revascularization
via angioplasty. It has been suggested that incomplete
Figure 2. Angina status among percutaneous transluminal coro-
nary angioplasty (PTCA) patients with complete revascularization
(CR) versus incomplete revascularization (IR) intended. CCS 5
Canadian Cardiovascular Society.
Table 6. Power Calculations (All PTCA Patients With CR vs. IR Intended)
Event
Actual Event Rates and Power Required for 80% Power
Rate Difference
CR 2 IR (%)
Risk
Ratio
%
Power
Rate Difference
CR 2 IR (%)
Risk
Ratio
Death 3.5 1.28 43 6.3 1.50
Cardiac death 0.1 1.01 6 5.3 1.66
MI 0.3 0.98 4 6.8 1.42
CABG 6.3 1.21 61 8.2 1.28
Abbreviations as in Table 1.
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anatomic but complete functional revascularization may
result in outcomes similar to those of complete anatomic
revascularization (33). However, when the analysis of free-
dom from death and freedom from MI was restricted to
patients with intended IR due to class C or to borderline
lesions in this study, outcomes were similar to those of the
entire cohort of patients with IR intended.
Conclusions. Five-year total and cardiac survival did not
differ between nondiabetic angioplasty patients with intended
incomplete revascularization and randomly assigned CABG
patients. Although freedom from MI at five years was signif-
icantly higher in nondiabetic CABG versus angioplasty
patients with intended incomplete revascularization (92.4% vs.
85.2%), whether this finding is genuine remains unclear in
light of the five-year MI-free rate of approximately 85%
observed in patients with complete revascularization intended.
Whereas intended incomplete revascularization seems to in-
crease the risk of subsequent CABG in patients undergoing
initial angioplasty, this strategy appears to be unrelated to the
five-year risk of repeat angioplasty, any revascularization
(CABG/angioplasty) or angina.
Taken together, our results suggest that experienced
angioplasty operators are able to determine which clinically
important lesions should and should not be intended and
attempted in patients with multivessel disease, without
compromising long-term patient survival.
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